Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
UroGen Pharma Ltd. - Ordinary Shares
(NQ:
URGN
)
35.64
-5.06 (-12.43%)
Delayed Quote
Updated: 10:35 AM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about UroGen Pharma Ltd. - Ordinary Shares
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
January 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate in the B. Riley Healthcare Conference
January 11, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
↗
December 07, 2023
Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of...
Via
Benzinga
Recap: UroGen Pharma Q3 Earnings
↗
November 14, 2023
Via
Benzinga
Preview: UroGen Pharma's Earnings
↗
November 13, 2023
Via
Benzinga
The Latest Analyst Ratings for UroGen Pharma
↗
October 04, 2023
Via
Benzinga
UroGen Pharma Reports Third Quarter 2023 Financial Results
November 14, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
November 13, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
↗
October 09, 2023
Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil.
Via
Benzinga
Topics
ETFs
Where UroGen Pharma Stands With Analysts
↗
July 31, 2023
Via
Benzinga
UroGen Pharma Ltd. (NASDAQ: URGN) Leading the Way in Friday Trading Based on Percentage Gain
July 28, 2023
Via
Investor Brand Network
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
October 03, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
September 11, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Ltd. (NASDAQ: URGN) Near the Top of Equities by Percentage Gain on 7/27
July 27, 2023
Via
Investor Brand Network
UroGen Pharma to Present at Upcoming Investor Conferences
August 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
August 17, 2023
Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash...
Via
Benzinga
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
August 10, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For August 10, 2023
↗
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 02, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
$10 Trillion Added In Market Cap; 2023’s Best And Worst Through July
↗
August 01, 2023
The US stock market has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023.
Via
Talk Markets
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Why Shares of UroGen Pharma Jumped Friday
↗
July 28, 2023
The company released positive top-line results for two studies for a bladder cancer treatment.
Via
The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
↗
July 28, 2023
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...
Via
Benzinga
Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
July 28, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Why UroGen Pharma Stock Is Gaining Today?
↗
July 27, 2023
UroGen Pharma Ltd (NASDAQ: URGN) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients...
Via
Benzinga
UroGen Announces $120 Million Private Placement of Ordinary Shares
July 27, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
